Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly - LARVOL DELTA

Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 25 mg in Patients with Type 2 Diabetes: A 24-Week Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with 28-Week Open-Label Extension (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

REMISSION INDUCTION IN 138000 PATIENTS WITH TYPE II DIABETES (ATTD 2026) - "General treatment consisted of Sitagliptin, Empagliflozin 12.5 mg, Metformin 500mg, long acting Glyclazid 60mg, Valsartan 80mg (to activate Glut-4). This is the first systematic study on type II diabetes with the goal of complete remission and probably cure. Although the results are not uniform, 56% are in maintained complete remission for 6-72 months."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=110 | Enrolling by invitation | Sponsor: Bahria University

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycemic Variability of Combination Therapies in T2DM (clinicaltrials.gov) - P4 | N=178 | Recruiting | Sponsor: JW Pharmaceutical

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study. (PubMed, Cardiovasc Diabetol) - "In patients with newly diagnosed T2D, 12 months of glycemic optimization was associated with changes in cardiac remodeling parameters despite no detectable changes in myocardial steatosis. The observed cardiac changes were more closely associated with concurrent reductions in adiposity markers than with changes in HbA1c, emphasizing weight management as a key target for early prevention of diabetic cardiomyopathy."

Journal • Observational data • Cardiomyopathy • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Balancing performance and sustainability: a white differential pulse voltammetry method for metformin and empagliflozin in plasma. (PubMed, Bioanalysis) - "Validated DPV-GCE enables rapid, sustainable MEF/EMP quantification in plasma without modification/chromatography. Proof-of-concept for routine therapeutic monitoring; clinical translation limited by spiked (not patient) samples."

Journal

WHEN A ZEBRA BECOMES A HORSE: AN UNDERRECOGNIZED PHENOTYPE OF TYPE 2 DIABETES (WRMC 2026) - "However, it was recently discovered that approximately one in four individuals with difficult-to-control type 2 diabetes has mild endogenous hypercortisolism, as defined by an abnormal low-dose dexamethasone suppression test (DST)...His A1c remained elevated despite an intensive regimen of insulin glargine, metformin, empagliflozin, and semaglutide...have demonstrated that the risk of cardiovascular events is lower in those who pursue treatment of the root of the cause, rather than treating associated complications. More studies are needed to determine the cost-effectiveness and long-term feasibility of cortisol-directed therapies to guide future management of difficult-to-control type 2 diabetes."

Cardiovascular • Cushing’s Disease • Diabetes • Endocrine Disorders • Hypertension • Metabolic Disorders • Obesity • Osteoporosis • Rheumatology • Solid Tumor • Type 2 Diabetes Mellitus

Euglycemic diabetic ketoacidosis following sleeve gastrectomy in a patient with type 2 diabetes on a sodium-glucose co-transporter 2 inhibitor: a case report and call for practice guidelines. (PubMed, AME Case Rep) - "A 62-year-old woman with T2D on insulin and severe obesity with an initial body mass index of 55 kg/m2 underwent an uneventful LGS and was discharged on empagliflozin and metformin for glycemic control...eDKA in patients who have undergone bariatric surgery may present with similar symptoms to post-bariatric surgical complications. This case emphasizes the need for clearer perioperative guidance."

Journal • Acute Kidney Injury • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Euglycemic diabetic ketoacidosis with gastrointestinal dysfunction following lung surgery in a patient on SGLT2 inhibitor: a case report. (PubMed, AME Case Rep) - "A 42-year-old woman with type 2 diabetes managed with metformin and empagliflozin (SGLT2i) underwent video-assisted thoracoscopic right upper lobectomy for suspected early lung cancer...Successful management requires early recognition, cessation of SGLT2i, adequate caloric intake via dextrose-containing fluids, and insulin to suppress ketogenesis. Preoperative discontinuation of SGLT2i 3-4 days prior to surgery is strongly recommended."

Journal • Cardiovascular • Diabetes • Gastrointestinal Disorder • Lung Cancer • Metabolic Disorders • Oncology • Pain • Pulmonary Disease • Solid Tumor • Type 2 Diabetes Mellitus

Bioequivalence Evaluation of Two Metformin/Empagliflozin Fixed-Dose Combination Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Crossover Study. (PubMed, Clin Pharmacol Drug Dev) - "No serious adverse events were reported. In conclusion, the test and reference formulations of metformin/empagliflozin FDC tablets were bioequivalent and well-tolerated under both fasting and fed conditions."

Clinical • Journal

Efficacy and Safety of Trelagliptin as an Add-on Therapy to Metformin and Empagliflozin in Elderly Chinese Patients with Type 2 Diabetes Mellitus: A Multicenter, Prospective, Real-World Study (CTMEA-RWS Study) (ChiCTR) - P4 | N=800 | Not yet recruiting | Sponsor: Zhengzhou Central Hospital; Zhengzhou Central Hospital

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Humanis Saglık Anonim Sirketi

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Jiangzhi Quban Recipe improves type 2 diabetes mellitus complicated with hyperlipidemia by multi-target regulation of the inflammation-metabolism network: network pharmacology analysis and clinical validation (PubMed, Nan Fang Yi Ke Da Xue Xue Bao) - "JZQBR improves T2DM complicated with hyperlipidemia possibly by multi-target regulation of the inflammation-metabolism network."

Journal • Diabetes • Dyslipidemia • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • APOE • IL1B • IL6 • TNFA

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin (clinicaltrials.gov) - P1 | N=111 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

New P1 trial • Obesity

Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes. (PubMed, Clin Nutr) - "The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option."

Journal • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ICDDTKZ26: Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (clinicaltrials.gov) - P=N/A | N=120 | Active, not recruiting | Sponsor: Nazarbayev University

New trial • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial. (PubMed, Diabetes Obes Metab) - "These results suggest that coadministration of empagliflozin safely improves glycemic control in Korean patients with T2DM uncontrolled by sitagliptin and metformin."

Journal • P3 data • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

CER-4-T2D: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (clinicaltrials.gov) - P=N/A | N=781430 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jan 2026

HEOR • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial. (PubMed, Diabetol Metab Syndr) - P2/3 | "12-month metformin therapy demonstrated renoprotective effects comparable to empagliflozin, with a greater effect observed among non-diabetics as an exploratory insight. Metformin's renal actions were linked to antifibrotic and favorable autophagy effects while, empagliflozin preserved mainly tubular injury. Safety issues were generally comparable."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease • BECN1 • KIM1 • TGFB1

Preconditioning strategies for stem cells and exosomes: Transformative potential in diabetic wound treatment: A review. (PubMed, Int J Biol Macromol) - "Recent advances and future directions in the optimization of these strategies are discussed, emphasizing their potential to transform stem cell therapies for diabetic wounds. We highlight that specific preconditioning methods-such as hypoxia and pharmacological agents like metformin or empagliflozin-can selectively enhance exosomal miRNA cargo (e.g., miR-126, miR-139-3p) and downstream angiogenic signaling.Our synthesis underscores the superior translational potential of ADSC-derived exosomes over cell therapies, especially when optimized via preconditioning tailored to the diabetic microenvironment."

Journal • Review • Pain • MIR126 • MIR139

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Humanis Saglık Anonim Sirketi

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients . (clinicaltrials.gov) - P4 | N=200 | Completed | Sponsor: Bahria University

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (clinicaltrials.gov) - P=N/A | N=396 | Active, not recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Trial completion date: Dec 2025 ➔ Jul 2026

Trial completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • Plasma NfL

Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes (clinicaltrials.gov) - P4 | N=172 | Completed | Sponsor: Bahria University | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

CT-L03-301: Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin (clinicaltrials.gov) - P3 | N=582 | Active, not recruiting | Sponsor: Celltrion | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus